LigaChem Biosciences (141080) Fundamentals 2026 — Revenue Analysis | SniperIQ
LigaChem Biosciences (141080) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩3.42T, trading at ₩93900.00 on the KOE. This SniperIQ fundamentals page covers LigaChem Biosciences's valuation, profitability (net margin -109.7%), revenue (₩141.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is LigaChem Biosciences's market cap?
LigaChem Biosciences (141080) has a market capitalization of approximately ₩3.42T, trading at ₩93900.00 on the KOE. Market cap moves with the live share price.
What is LigaChem Biosciences's P/E ratio?
LigaChem Biosciences's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 7.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is LigaChem Biosciences?
LigaChem Biosciences runs a net profit margin of -109.7%, a gross margin of 87.4%, and an operating margin of -123.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does LigaChem Biosciences generate?
LigaChem Biosciences reported revenue of ₩141.6B for fiscal year 2025, with net income of -₩74.3B and earnings per share (EPS) of -2041.71. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does LigaChem Biosciences pay a dividend?
LigaChem Biosciences does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is LigaChem Biosciences financially healthy?
LigaChem Biosciences carries a debt-to-equity ratio of 0.01x and a current ratio of 10.12x, with a market beta of 0.38. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is LigaChem Biosciences a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For LigaChem Biosciences (141080) the key facts are: market cap ₩3.42T, revenue ₩141.6B, 52-week range 90100-225000. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track LigaChem Biosciences's full fundamentals live
Get LigaChem Biosciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.